TW202434280A - 用於治療嚼肌肥大之方法 - Google Patents

用於治療嚼肌肥大之方法 Download PDF

Info

Publication number
TW202434280A
TW202434280A TW112144521A TW112144521A TW202434280A TW 202434280 A TW202434280 A TW 202434280A TW 112144521 A TW112144521 A TW 112144521A TW 112144521 A TW112144521 A TW 112144521A TW 202434280 A TW202434280 A TW 202434280A
Authority
TW
Taiwan
Prior art keywords
units
botulinum toxin
masseter
dose
kit
Prior art date
Application number
TW112144521A
Other languages
English (en)
Chinese (zh)
Inventor
伊莉莎白 李
貝塔 波溫
克莉絲汀 梭莫基
約翰 Ｄ 羅傑斯
Original Assignee
美商歐樂根公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商歐樂根公司 filed Critical 美商歐樂根公司
Publication of TW202434280A publication Critical patent/TW202434280A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Traffic Control Systems (AREA)
TW112144521A 2018-09-13 2019-09-16 用於治療嚼肌肥大之方法 TW202434280A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731064P 2018-09-13 2018-09-13
US62/731,064 2018-09-13

Publications (1)

Publication Number Publication Date
TW202434280A true TW202434280A (zh) 2024-09-01

Family

ID=68069888

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112144521A TW202434280A (zh) 2018-09-13 2019-09-16 用於治療嚼肌肥大之方法
TW108133293A TWI835858B (zh) 2018-09-13 2019-09-16 用於治療嚼肌肥大之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108133293A TWI835858B (zh) 2018-09-13 2019-09-16 用於治療嚼肌肥大之方法

Country Status (11)

Country Link
US (3) US20200085923A1 (https=)
EP (1) EP3849585A1 (https=)
JP (2) JP2022500417A (https=)
KR (1) KR20210057106A (https=)
CN (1) CN112955166A (https=)
AU (2) AU2019337656A1 (https=)
BR (1) BR112021004776A2 (https=)
CA (1) CA3112227A1 (https=)
MX (1) MX2021002993A (https=)
TW (2) TW202434280A (https=)
WO (1) WO2020056204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152107A (ko) * 2021-02-26 2023-11-02 이온 바이오파마, 인크. 두통을 치료하는 데 사용하기 위한 신경독소 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3368071B1 (en) * 2015-10-29 2022-01-26 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
WO2020056204A1 (en) 2020-03-19
KR20210057106A (ko) 2021-05-20
EP3849585A1 (en) 2021-07-21
MX2021002993A (es) 2021-08-11
JP2024177185A (ja) 2024-12-19
TW202023606A (zh) 2020-07-01
AU2025226702A1 (en) 2025-09-25
TWI835858B (zh) 2024-03-21
US20200085923A1 (en) 2020-03-19
US20230080740A1 (en) 2023-03-16
BR112021004776A2 (pt) 2021-11-09
JP2022500417A (ja) 2022-01-04
AU2019337656A1 (en) 2021-05-06
CN112955166A (zh) 2021-06-11
CA3112227A1 (en) 2020-03-19
US20230083250A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US5183462A (en) Controlled administration of chemodenervating pharmaceuticals
Nixdorf et al. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain
Klein Complications and adverse reactions with the use of botulinum toxin
US10729751B2 (en) Injection paradigm for administration of botulinum toxins
US20250064905A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
JP2010106026A (ja) 筋肉へのクロストリディウムトキシンの効果を判定するための方法
JP2020511428A (ja) 唾液腺炎の治療におけるボツリヌス神経毒素の改善された使用
AU2025226702A1 (en) Methods for treatment of masseter muscle hypertrophy
Lee et al. A multicenter phase II study evaluating the safety and efficacy of botulax in Asian patients with benign masseteric hypertrophy
US20190183987A1 (en) Neurotoxins for use in minimizing scarring
JP2024543080A (ja) ボツリヌス毒素組成物
US20250186328A1 (en) Use of botulinum toxins for the treatment of platysma prominence
Govindaraju et al. Botulinum toxin-An Innovative Treatment Approach in Dental Practice
Cho et al. Advanced Techniques in Botulinum Toxin Injection
WO2025064729A1 (en) Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
AU2024274999A1 (en) Botulinum toxin for treating peripheral neuropathic pain
Bhattacharya The Effect of Botulinum Toxin Injections on Nasolabial Fold
Montecucco et al. 169. A WEISSELLA ORYZAE BOTULINUM-LIKE TOXIN CLEAVES VAMP WITHIN THE JUXTAMEMBRANE DOMAIN
HK40000453A (en) Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect